Exchange: AMEX Industry: Medical Devices
-0.80% $2.28
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 53.52 mill |
EPS: | -0.820 |
P/E: | -2.78 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 23.46 mill |
Avg Daily Volume: | 0.0253 mill |
RATING 2024-03-27 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.78 | sector: PE 12.30 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.13x |
Company: PE -2.78 | industry: PE 21.09 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.12 - 2.44 ( +/- 6.97%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-23 | Kester Thomas J | Buy | 29 032 | Common Stock |
2024-01-23 | Kester Thomas J | Buy | 11 098 | Options to purchase common stock (right to buy) |
2024-01-23 | Verta Patrick | Buy | 85 720 | Common Stock |
2024-01-23 | Verta Patrick | Buy | 32 768 | Options to purchase common stock (right to buy) |
2024-01-23 | Gleason Shane Thomas | Buy | 238 625 | Common Stock |
INSIDER POWER |
---|
98.06 |
Last 99 transactions |
Buy: 7 620 190 | Sell: 72 371 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.28 (-0.80% ) |
Volume | 0.0250 mill |
Avg. Vol. | 0.0253 mill |
% of Avg. Vol | 98.80 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.